President Trump’s planned pharmaceutical tariffs threaten to hit many of the most common and well-known drugs that Americans take.
Tag: Generic Brands and Products
Where U.S. Medicines Are Made and How Trump’s Tariffs Could Affect Them
President Trump’s planned pharmaceutical tariffs threaten to hit many of the most common and well-known drugs that Americans take.
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
Many middle-income countries are left out of the deal, widening a gulf in access to critical medicines.
This Cystic Fibrosis Drug Is a ‘Miracle’ but These Families Can’t Get It
Vertex Pharmaceuticals is not making its drug, Trikafta, available in poorer countries, where thousands of diagnosed patients stand to benefit.
A New Shot Guards Against H.I.V., but Access for Africans Is Uncertain
An injection every two months rather than a daily pill could shield many more women from the virus, but it is unavailable in places that need it most.
Seeking Covid Pills, Poor Nations Fear Repeat of AIDS Crisis
The antiviral pills, plentiful in the United States, are scarce overseas. Health groups and the White House want to expand access but face obstacles that evoke the H.I.V. epidemic.
Will New Covid Treatments Be as Elusive for Poor Countries as Vaccines?
Merck has taken a step to make its antiviral pill available in poor nations, but many obstacles remain for broad access to coronavirus drugs.
To Drive Down Insulin Prices, W.H.O. Will Certify Generic Versions
About 80 million people with diabetes around the world need the hormone, and half of them can’t afford it. Creating competition could help, the agency said.
Drug Companies Are Focusing on the Poor After Decades of Ignoring Them
The pharmaceutical industry once sued to keep AIDS drugs from dying Africans. Now companies boast of their efforts to get medicines to the developing world.
Global Health: Gilead Will Donate Truvada to U.S. for H.I.V. Prevention
The manufacturer will provide enough of the drug to supply 200,000 patients annually for more than a decade. Critics said it would not be enough to end the AIDS epidemic and questioned the company’s motives.